• Imbruvica


Facts of Imbruvica (Ibrutinib)Capsules ?

  • Medicine Name: Imbruvica
  • Date of Approval: 13.11.2013
  • Company Name: Janssen Biotech, Inc.

Product Description

What is IMBRUVICA® ?

IMBRUVICA® is a prescription medicine used to treat people with:

  • Chronic lymphocytic leukemia (CLL) who have received at least one prior treatment
  • Chronic lymphocytic leukemia (CLL) with 17p deletion
  • Mantle cell lymphoma (MCL) who have received at least one prior treatment

For MCL IMBRUVICA® is approved on response. Data are not yet available to show if IMBRUVICA® improves survival or symptoms

The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) capsules for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy

What are the general information about the safe and effective use of IMBRUVICA ?

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA for a condition for which it was not prescribed. Do not give IMBRUVICA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA that is written for health professionals.

It is not known if IMBRUVICA® is safe and effective in children.


There are no reviews yet.

Be the first to review “Imbruvica”